Completed PHASE1/PHASE2 INTERVENTIONAL NCT00233909

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Sponsor: Kanisa Pharmaceuticals

Conditions Leukemia, Myeloid

Interventions Zosuquidar gemtuzumab ozogamicin

Updated 5 times since 2017 Last updated: Mar 28, 2008 Started: Oct 31, 2005 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00233909, this PHASE1/PHASE2 trial focuses on Leukemia, Myeloid and remains completed. Sponsored by Kanisa Pharmaceuticals, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kanisa Pharmaceuticals

Data source: Kanisa Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.